Gastroenterology

Research Shows Reduced Emergency Department Utilization from Patients Accessing Oshi Health Virtual Multidisciplinary GI Care

Retrieved on: 
Wednesday, November 29, 2023

NEW YORK, Nov. 29, 2023 /PRNewswire-PRWeb/ -- Research findings showing reduced emergency department (ED) utilization in patients enrolled in Oshi Health's virtual multidisciplinary GI care were presented earlier this month at the American Public Health Association's (APHA) Annual Meeting, demonstrating the impact of preventive, high-touch, value-based care for conditions that affect one in four Americans.

Key Points: 
  • NEW YORK, Nov. 29, 2023 /PRNewswire-PRWeb/ -- Research findings showing reduced emergency department (ED) utilization in patients enrolled in Oshi Health's virtual multidisciplinary GI care were presented earlier this month at the American Public Health Association's (APHA) Annual Meeting, demonstrating the impact of preventive, high-touch, value-based care for conditions that affect one in four Americans.
  • Virtual-first care providers like Oshi Health , the leading virtual digestive health center of excellence, present an opportunity to better support patients with complex care needs.
  • Oshi provides rapid access to GI care for patients, delivering high-touch, multidisciplinary care and telehealth appointments with GI-specialized physicians, dietitians, psychologists, health coaches, and care coordinators – all working together to help patients achieve lasting symptom resolution and control.
  • Oshi Health is the only virtual GI practice with support from the two leading GI societies and renowned GI researchers.

U.S. News to Debut Best Ambulatory Surgery Centers in 2024

Retrieved on: 
Tuesday, November 28, 2023

WASHINGTON, Nov. 28, 2023 /PRNewswire/ -- U.S. News & World Report, the global authority in health care rankings and consumer advice, today announced the addition of Best Ambulatory Surgery Centers to its annual series of ratings evaluating health care sites. With more than half of all U.S. surgeries categorized as same-day procedures, patients in need of a knee replacement, a colonoscopy or any one of numerous other procedures will now be able to find the objective data they need to choose the same-day specialized surgery center that best meets their health care needs.

Key Points: 
  • WASHINGTON, Nov. 28, 2023 /PRNewswire/ -- U.S. News & World Report, the global authority in health care rankings and consumer advice, today announced the addition of Best Ambulatory Surgery Centers to its annual series of ratings evaluating health care sites.
  • The Best Ambulatory Surgery Centers methodology will combine relevant measures to produce a composite rating for each of several key specialty areas: orthopedics & spine, gastroenterology, urology, and ophthalmology.
  • "These upcoming Ambulatory Surgery Centers ratings rely on our data collaboration with CareJourney and are a meaningful step forward in providing data driven health care insights to consumers," said Sumita Singh, senior vice president and general manager of Healthcare at U.S. News.
  • With its planned release in the second quarter of 2024, Best Ambulatory Surgery Centers complements U.S. News' expanding health rankings and ratings including Best Hospitals, Best Children's Hospitals, Best Senior Living, Best Nursing Homes, Best OTC Medicine & Health Products and Best Diets.

Patient Affordability and Access to Specialty and Biologic Medications Just Got Easier

Retrieved on: 
Tuesday, November 28, 2023

CRANBERRY TOWNSHIP, Pa., Nov. 28, 2023 /PRNewswire/ -- Annexus Health, Inc., the leading healthcare technology company that is revolutionizing the patient access journey through its innovative solutions, today announced a strategic partnership with WeInfuse, the premier technology and consulting provider for infusion therapy and medication delivery in the United States.

Key Points: 
  • AssistPoint is a comprehensive patient financial assistance management solution for infusion centers, community practices, multispecialty providers, hospitals, institutions, and specialty pharmacies.
  • The Adparo team utilizes AssistPoint to identify, enroll patients in, and manage financial assistance and other access services.
  • "Proactively managing patient financial assistance is imperative to infusion centers, and our suite of products and services empowers them to do that," said Annexus Health Co-Founder and President Brad Frazier.
  • "By partnering with Annexus Health, we can now offer our clients powerful, customizable solutions to streamline and automate the patient financial assistance process to make infusion therapy more accessible and affordable."

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Retrieved on: 
Monday, November 13, 2023

ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, are pleased to announce the Health Canada approval for Bylvay™ (odevixibat) for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis (PFIC), a progressive and life-threatening liver disease.  Bylvay is the first medication approved in Canada for the treatment of pruritus in patients aged six months or older with PFIC.

Key Points: 
  • Bylvay is the first medication approved in Canada for the treatment of pruritus in patients aged six months or older with PFIC.
  • "At Medison, accelerating patients' access to innovative treatments is leading all that we do, so we are pleased and proud to bring Bylvay to patients in Canada," said Gil Gurfinkel, CEO at Medison Pharma.
  • "Until today, surgery was the only treatment option available for PFIC patients," said Mr. Walter Perez, President, Progressive Familial Intrahepatic Cholestasis Advocacy and Resource Network and father of a child living with PFIC.
  • We are extremely pleased that a less invasive treatment option is now available."

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Retrieved on: 
Monday, November 13, 2023

ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ -- Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, are pleased to announce the Health Canada approval for Bylvay™ (odevixibat) for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis (PFIC), a progressive and life-threatening liver disease.  Bylvay is the first medication approved in Canada for the treatment of pruritus in patients aged six months or older with PFIC.

Key Points: 
  • Bylvay is the first medication approved in Canada for the treatment of pruritus in patients aged six months or older with PFIC.
  • "At Medison, accelerating patients' access to innovative treatments is leading all that we do, so we are pleased and proud to bring Bylvay to patients in Canada," said Gil Gurfinkel, CEO at Medison Pharma.
  • "Until today, surgery was the only treatment option available for PFIC patients," said Mr. Walter Perez, President, Progressive Familial Intrahepatic Cholestasis Advocacy and Resource Network and father of a child living with PFIC.
  • We are extremely pleased that a less invasive treatment option is now available."

Top Gastroenterology and Liver Disease Specialist, Dr. David P. Yamini, Receives Castle Connolly's 2023 Top Doctor® Award

Retrieved on: 
Thursday, November 9, 2023

BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly. Dr. Yamini is an accomplished physician who is double board-certified in gastroenterology and internal medicine. He serves patients in Santa Monica and Beverly Hills, CA, treating diseases and disorders of the digestive system. Dr. Yamini's medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team. Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com and in a wide variety of partner publications, magazines and affiliate websites. Around 7% of the nation's top board-certified, licensed physicians have been selected as Castle Connolly Top Doctors in their regions for their specialties. Individuals do not and cannot pay to be selected as a Castle Connolly Top Doctor. Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists. Dr. Yamini offers expertise in issues involving the digestive tract, biliary system, liver and pancreas, with a proficiency in endoscopic retrograde cholangiopancreatography (ERCP). He takes a comprehensive approach to diagnosing and treating patients with all types of gastrointestinal (GI) problems and disorders that affect the small and large intestine, stomach, esophagus, gallbladder, liver and pancreas, including inflammatory bowel disease (Crohn's, ulcerative colitis), indigestion (dyspepsia), small intestinal bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS). Dr. Yamini provides his patients with a superior level of compassionate and attentive personalized care.

Key Points: 
  • BEVERLY HILLS, Calif., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Dr. David Yamini has been selected as a 2023 Top Doctor® by Castle Connolly.
  • Dr. Yamini's medical education, training, hospital appointments and disciplinary history were rigorously screened by the Castle Connolly physician-led research team.
  • Dr. David Yamini offers advanced diagnostic and therapeutic procedures and has established a reputation as one of the best Los Angeles gastroenterologists and liver disease specialists .
  • "It is such an honor to be recognized by my peers for this award," says Dr. David Yamini.

EQS-News: Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Retrieved on: 
Tuesday, December 12, 2023

BERKELEY, US – MAINZ, Germany – DECEMBER 12, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – DECEMBER 12, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its active participation alongside Polish partner TestDNA at two significant gastroenterology conferences in Poland, strengthening their commitment to advancing colorectal cancer (CRC) detection and gastroenterological innovation.
  • The first attended conference, the 17th Conference: Advances in Gastroenterology, ran from December 8th to 9th, 2023, in Poznań.
  • Following this, Mainz Biomed will be taking part in the 10th Gdańsk Gastroenterology Symposium which runs from January 12th to 13th, 2024.
  • Darin Leigh, Chief Commercial Officer of Mainz Biomed, expressed enthusiasm about the upcoming conferences, stating, "Our collaboration with TestDNA at these prestigious conferences is a testament to our shared commitment to revolutionize CRC detection and improve patient outcomes.

Evoke Pharma Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced its financial results for the third quarter ended September 30, 2023, and recent corporate developments.

Key Points: 
  • 38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year
    21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year
    SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced its financial results for the third quarter ended September 30, 2023, and recent corporate developments.
  • Prescription fills in Q3 2023 were also up 21% from Q2 2023,” commented David A. Gonyer, R.Ph., Chief Executive Officer of Evoke Pharma.
  • For the third quarter of 2023, net product sales were $1,562,860 compared to $832,100 during the third quarter of 2022.
  • For the third quarter of 2023, selling, general and administrative expenses were approximately $3.1 million compared to $2.6 million for the third quarter of 2022.

Alliance Promotion Microbiote To Welcome Ferring Pharmaceuticals, Pelican Health and Polepharma as New Members

Retrieved on: 
Thursday, November 9, 2023

With more than 20 current members, APM today welcomes Ferring Pharmaceuticals, Pelican Health and Polepharma, three major contributors to the development, the production, and the commercialization of microbiome-based therapeutic and diagnostic innovations for patients.

Key Points: 
  • With more than 20 current members, APM today welcomes Ferring Pharmaceuticals, Pelican Health and Polepharma, three major contributors to the development, the production, and the commercialization of microbiome-based therapeutic and diagnostic innovations for patients.
  • Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology.
  • Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth.
  • www.polepharma.com
    Hervé Affagard, President of Alliance Promotion Microbiote states "We are thrilled to extend a warm welcome to Ferring Pharmaceuticals, Pelican Health, and Polepharma as they join our microbiome-focused association.

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Retrieved on: 
Wednesday, November 8, 2023

BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.

Key Points: 
  • BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
  • As a result of the transaction, Intercept has become a wholly owned subsidiary of Alfasigma, and the common stock of Intercept has ceased to be traded on the NASDAQ Stock Market.
  • Stefano Golinelli, Chairman of Alfasigma, commented: “At Alfasigma, the passion we have for Pharmaceuticals is in our DNA - and a driver for our ambitious international growth plans.
  • Francesco Balestrieri, CEO of Alfasigma, added: “Today, we complete a transformational acquisition which strongly aligns with our strategy of building a solid presence in gastroenterology and hepatology, Alfasigma’s core business areas.